Status:
TERMINATED
Open-label Extension to Protocol 1042-0500
Lead Sponsor:
Marinus Pharmaceuticals
Conditions:
Infantile Spasms
Eligibility:
All Genders
4-24 years
Phase:
PHASE2
Brief Summary
To allow open-label extension to patients who have completed Protocol 1042-0500
Detailed Description
Patient should have completed all scheduled clinical study visits in the double blind, controlled trial (Protocol 1042-0500) and have been deemed eligible (had a response to treatment) by the Investig...
Eligibility Criteria
Inclusion
- Have completed all scheduled clinical study visits in the previous Protocol 1042 0500 and have been deemed eligible (no SAEs thought to be drug related and had a response to treatment) by the Investigator.
- Be diagnosed with IS regardless of etiology. Diagnostic Criteria: Seizures consisting of single or repetitive short muscular contractions leading to flexion or extension. Spasms may be characterized as tonic or myoclonic contractions, may occur singly or in clusters, and typically occur bilaterally and symmetrically. The EEG pattern must be consistent with the diagnosis of IS (hypsarrhythmia, modified hypsarrhythmia, multifocal spike wave discharges, etc).
- Have a 24 hour vEEG recording confirming the diagnosis of IS.
- Have had a magnetic resonance imaging (MRI) performed to determine any possible causes of IS.
- Have been previously treated with 3 AEDs or fewer.
- Have a parent/guardian who is properly informed of the nature and potential risks and benefits of the clinical study, is willing and capable of complying with all clinical study procedures, and has given informed consent in writing prior to entering the clinical study.
Exclusion
- Current treatment with more than 2 concomitant AEDs.
- Have an active CNS infection, demyelinating disease, degenerative neurological disease, or CNS disease deemed progressive (with the exception of tuberous sclerosis) as evaluated by brain MRI.
- Have any disease or condition (medical or surgical) at Screening that might compromise the hematologic, cardiovascular, pulmonary, renal, GI, or hepatic systems; or other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the investigational product, or would place the subject at increased risk.
- Aspartate transaminase (AST), alanine transaminase (ALT), or total bilirubin greater than 4 times the upper limit of laboratory normal or any clinical laboratory value deemed clinically significant by the Investigator.
- History of recurrent status epilepticus.
- Have been exposed to any other investigational drug within 30 days prior to enrollment.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00442104
Start Date
January 1 2007
End Date
March 1 2009
Last Update
May 28 2024
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Los Angeles
Los Angeles, California, United States, 90027
2
Mattel Children's Hospital at UCLA
Los Angeles, California, United States, 90095
3
Children's National Medical Center
Washington D.C., District of Columbia, United States, 20010
4
Miami Children's Hospital, The Brain Institute
Miami, Florida, United States, 33155